CardioDx hired Khush F. Mehta as CEO and a member of the board of directors on June 1.
Mehta joined the company from Siemens, where he served as the global head of the healthcare enterprise solutions division. He was also the chief strategy officer of Siemens Healthcare from 2010 to 2014.
Mehta succeeds David Levison, who was named the company’s chief strategy officer, where he will lead business development, health payer coverage and development of next generation technologies. Levison founded the company in 2004.
CardioDX, a privately held molecular diagnostics company, manufactures the Corus CAD blood test that provides information on the likelihood of a person having obstructive coronary artery disease. The test accounts for a person’s age, sex and gene expression and calculates a score. A higher score means a person is more likely to have a significant narrowing or blockage in the heart arteries.
CardioDX has raised $284 million in total equity funding from 25 investors, according to CrunchBase. The company raised $12.37 million in series D funding on Feb. 22, two months after Timothy Henn joined CardioDX as chief financial officer.